Cargando…

Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A()()

OBJECTIVES: To compare rates of unintended pregnancy, method continuation and reasons for removal among women using the 52-mg levonorgestrel (daily release 20 microg) levonorgestrel IUD (LNG-IUD) or the copper T 380 A (TCu380A) intrauterine device. STUDY DESIGN: This was an open-label 7-year randomi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rowe, Patrick, Farley, Tim, Peregoudov, Alexandre, Piaggio, Gilda, Boccard, Simone, Landoulsi, Sihem, Meirik, Olav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357727/ https://www.ncbi.nlm.nih.gov/pubmed/26916172 http://dx.doi.org/10.1016/j.contraception.2016.02.024

Ejemplares similares

Corrigendum to “Rowe P et al. safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A” [Contraception 2016;93:498–506]
por: Rowe, Patrick, et al.
Publicado: (2016)

Heavy Menstrual Bleeding Treatment With a Levonorgestrel 52-mg Intrauterine Device
por: Creinin, Mitchell D., et al.
Publicado: (2023)

Five-Year Contraceptive Efficacy and Safety of a Levonorgestrel 52-mg Intrauterine System
por: Teal, Stephanie B., et al.
Publicado: (2019)

Consecutive Use of the 52 mg Levonorgestrel-releasing Intrauterine System: Variations in Bleeding Patterns
por: Wittmann, Barbara Zantut, et al.
Publicado: (2020)

Impact of immediate postpartum insertion of TCu380A on the quantity and duration of lochia discharges in Tanzania
por: Muganyizi, Projestine Selestine, et al.
Publicado: (2021)

Continuation Rates of the 52-mg Levonorgestrel-releasing Intrauterine System according to the Primary Reason for its Use
por: Miranda, Laura, et al.
Publicado: (2021)

A one-year cohort study of complications, continuation, and failure rates of postpartum TCu380A in Tanzania
por: Rwegoshora, France John, et al.
Publicado: (2020)

Is 2-dimensional transvaginal ultrasonography necessary 6 weeks after insertion of the levonorgestrel 52-mg intrauterine device?
por: van der Heijden, Patty A.H.H., et al.
Publicado: (2022)

Extended Effectiveness of the Etonogestrel-Releasing Contraceptive Implant and the 20 µg Levonorgestrel-Releasing Intrauterine System for 2 Years Beyond U.S. Food and Drug Administration Product Labeling
por: Ali, Moazzam, et al.
Publicado: (2017)

Five-year Contraceptive Use of 52-mg Levonorgestrel Releasing Intrauterine System in Young Women, Menstrual Patterns, and New Contraceptive Choice
por: de Oliveira, Elaine Cristina Fontes, et al.
Publicado: (2023)

Chronic Urticaria Suspected to be Caused by a 13.5 mg Levonorgestrel Intrauterine Device (Skyla®)
por: Ganguli, Malika P, et al.
Publicado: (2023)

New intrauterine technologies for contraception and treatment in nulliparous/adolescent and parous women
por: Wildemeersch, D.
Publicado: (2009)

Non-contraceptive applications of the levonorgestrel intrauterine system
por: Rodriguez, Maria Isabel, et al.
Publicado: (2010)

Role of the levonorgestrel intrauterine system in effective contraception
por: Attia, Abdelhamid M, et al.
Publicado: (2013)

Use of naproxen versus intracervical block for pain control during the 52-mg levonorgestrel-releasing intrauterine system insertion in young women: a multivariate analysis of a randomized controlled trial
por: de Oliveira, Elaine Cristina Fontes, et al.
Publicado: (2021)

Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant
por: Ali, Moazzam, et al.
Publicado: (2016)

Estudio retrospectivo de la aceptación y uso del DIU TCu-380 en la Unidad Médica Rural Santa Rosa, Mpio. de Gutiérrez Zamora, Veracruz /
por: Pech Bautista, Eduardo
Publicado: (1995)

Levonorgestrel-Releasing Intrauterine System and Iron Overload Syndrome
por: Vieira da Motta, Marcia, et al.
Publicado: (2013)

The role of levonorgestrel intrauterine systems in the treatment of symptomatic fibroids
por: Wrona, Wojciech, et al.
Publicado: (2017)

Levonorgestrel-Releasing Intrauterine System Use in Perimenopausal Women
por: Joo, Jong-Kil, et al.
Publicado: (2021)

"Revisión bibliográfica de detección de subunidad B de gonadotropina coriónica humana en sangre de pacientes que utilizan DIU (TCu 380 A) como método anticonceptivo/
por: Ortíz Dorantes, Rodolfo
Publicado: (1993)

The Levonorgestrel Intrauterine System: A Pragmatic View of an Excellent Contraceptive
por: Jacobstein, Roy, et al.
Publicado: (2015)

The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability
por: Beatty, Megan N, et al.
Publicado: (2009)

Abnormal uterine bleeding in midlife: The role of levonorgestrel intrauterine system
por: Shawki, Osama, et al.
Publicado: (2013)

Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases
por: Kim, Mi-La, et al.
Publicado: (2013)

Levonorgestrel-Releasing Intrauterine Device-Related Acute Liver Injury
por: Cheema, Hira Imad, et al.
Publicado: (2017)

Use of the Levonorgestrel Intrauterine Device in Women With Type 2 Diabetes
por: Lang, Benjamin, et al.
Publicado: (2018)

Levonorgestrel intrauterine system associated amenorrhea: a systematic review and metaanalysis
por: Sergison, Jill E., et al.
Publicado: (2019)

Uterine Perforation by Levonorgestrel-Releasing Intrauterine Device: A Case Report
por: Roman, Jose D
Publicado: (2022)

Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system
por: Kailasam, Chandra, et al.
Publicado: (2008)

Levonorgestrel intrauterine system: Current role in management of heavy menstrual bleeding
por: Magon, Navneet, et al.
Publicado: (2013)

The Levonorgestrel Intrauterine System: Reasons to Expand Access to the Public Sector of Africa
por: Hubacher, David
Publicado: (2015)

The levonorgestrel intrauterine device in Australia: analysis of prescribing data 2008–2012
por: Bingham, Amie L., et al.
Publicado: (2018)

Reversible Cerebral Vasoconstriction Syndrome Associated with Levonorgestrel-Releasing Intrauterine System
por: Choi, Sangwon, et al.
Publicado: (2021)

Clinical Efficacy of Dienogest versus Levonorgestrel-Releasing Intrauterine System for Adenomyosis
por: Yang, Siyuan, et al.
Publicado: (2022)

Effects of Levonorgestrel-Releasing Intrauterine Device Therapy on Ovarian Reserve in Menorrhagia
por: Gök, Soner, et al.
Publicado: (2022)

Lack of Association between Cu T-380A Intrauterine Device and Secondary Infertility in Iran
por: Abdinasab, Mahnaz, et al.
Publicado: (2017)

O.5.2-10 Barriers to physical activity among parous women postpartum: a qualitative study in Denmark
por: Bueno, Solvej Videbæk, et al.
Publicado: (2023)

Structural characterization of borneol dehydrogenase from Pseudomonas sp. TCU-HL1
por: Khine, Aye Aye, et al.
Publicado: (2020)

The lost intrauterine levonorgestrel-releasing system in women with adenomyosis: A case report
por: Gunardi, Eka Rusdianto, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dc17qk2blhvcr36tcjf7fsmkoi